Ajanta Pharma 미래 성장

Future 기준 확인 3/6

Ajanta Pharma (는) 각각 연간 16.4% 및 11.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 16.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 23.8% 로 예상됩니다.

주요 정보

16.4%

수익 성장률

16.4%

EPS 성장률

Pharmaceuticals 수익 성장	17.5%
매출 성장률	11.4%
향후 자기자본 수익률	23.8%
애널리스트 커버리지	Good
마지막 업데이트	12 Dec 2024

최근 미래 성장 업데이트

Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Oct 31

Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 04

Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

May 05

Recent updates

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Dec 15

Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Oct 31

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Sep 10

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Aug 23

Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 04

Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E

Aug 01

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Jun 01

Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

May 05

Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price

Apr 05

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Feb 23

Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Dec 23

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

Aug 26

These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well

Feb 07

I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut

Feb 06

Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Dec 13

Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50

Oct 31

Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching

Sep 22

Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?

Sep 08

Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Aug 26

Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet

Jul 07

Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?

Jun 14

Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?

May 15

Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why

Apr 10

Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Mar 11

Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?

Feb 24

The Ajanta Pharma (NSE:AJANTPHARM) Share Price Is Up 56% And Shareholders Are Holding On

Jan 30

What Can We Make Of Ajanta Pharma's (NSE:AJANTPHARM) CEO Compensation?

Jan 18

수익 및 매출 성장 예측

NSEI:AJANTPHARM - 애널리스트의 미래 추정치 및 과거 재무 데이터 (INR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2027	59,429	13,179	10,903	11,809	7
3/31/2026	53,123	11,204	8,444	9,799	10
3/31/2025	47,234	9,564	7,822	9,219	9
9/30/2024	44,908	8,750	9,127	11,625	N/A
6/30/2024	43,326	8,538	N/A	N/A	N/A
3/31/2024	42,087	8,162	6,327	7,851	N/A
12/31/2023	40,365	7,357	N/A	N/A	N/A
9/30/2023	39,031	6,602	6,610	8,199	N/A
6/30/2023	38,128	6,215	N/A	N/A	N/A
3/31/2023	37,426	5,880	6,176	7,921	N/A
12/31/2022	37,311	6,169	N/A	N/A	N/A
9/30/2022	35,972	6,742	5,027	6,613	N/A
6/30/2022	35,439	7,136	N/A	N/A	N/A
3/31/2022	33,410	7,127	4,129	5,617	N/A
12/31/2021	32,275	7,207	N/A	N/A	N/A
9/30/2021	31,384	7,056	3,607	5,379	N/A
6/30/2021	29,695	6,799	N/A	N/A	N/A
3/31/2021	28,897	6,539	4,047	5,763	N/A
12/31/2020	28,148	6,238	N/A	N/A	N/A
9/30/2020	27,173	5,547	3,593	5,334	N/A
6/30/2020	26,441	5,008	N/A	N/A	N/A
3/31/2020	25,879	4,677	2,174	4,568	N/A
12/31/2019	24,211	4,274	N/A	N/A	N/A
9/30/2019	22,550	3,868	1,451	4,409	N/A
6/30/2019	21,563	3,958	N/A	N/A	N/A
3/31/2019	20,554	3,870	315	3,745	N/A
12/31/2018	20,654	3,926	N/A	N/A	N/A
9/30/2018	21,674	4,731	N/A	N/A	N/A
6/30/2018	21,636	4,796	N/A	N/A	N/A
3/31/2018	21,258	4,686	N/A	2,811	N/A
12/31/2017	20,590	4,882	N/A	N/A	N/A
9/30/2017	20,050	4,833	N/A	N/A	N/A
6/30/2017	19,805	4,821	N/A	N/A	N/A
3/31/2017	19,833	5,068	N/A	6,093	N/A
12/31/2016	19,386	4,908	N/A	N/A	N/A
9/30/2016	18,821	4,622	N/A	N/A	N/A
6/30/2016	18,072	4,350	N/A	N/A	N/A
3/31/2016	17,340	4,156	N/A	3,261	N/A
12/31/2015	16,809	3,692	N/A	N/A	N/A
9/30/2015	16,160	3,510	N/A	N/A	N/A
6/30/2015	15,502	3,340	N/A	N/A	N/A
3/31/2015	14,736	3,099	N/A	2,794	N/A
3/31/2014	12,083	2,339	N/A	2,124	N/A

애널리스트 미래 성장 예측

수입 대 저축률: AJANTPHARM 의 연간 예상 수익 증가율( 16.4% )이 saving rate( 6.7% 보다 높습니다. ).

수익 vs 시장: AJANTPHARM 의 연간 수익( 16.4% ) Indian 시장( 18.1% 보다 느리게 성장할 것으로 예상됩니다. 18.1% 연간).

고성장 수익: AJANTPHARM 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: AJANTPHARM 의 수익(연간 11.4% ) Indian 시장( 10.5% 보다 빠르게 성장할 것으로 예상됩니다. 10.5% 연간).

고성장 수익: AJANTPHARM 의 수익(연간 11.4% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: AJANTPHARM 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 23.8 %)

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/21 20:06
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2024/03/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Ajanta Pharma Limited 25 애널리스트 중 10 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Nikhil Mathur	Ambit Capital
null null	Anand Rathi Shares and Stock Brokers Limited
Rashmi Sancheti Shetty	Anand Rathi Shares and Stock Brokers Limited

Ajanta Pharma 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Price target increased by 7.1% to ₹2,874

Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Price target increased by 7.6% to ₹2,664

Price target increased by 7.4% to ₹2,440

Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

Recent updates

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited to Report Q2, 2025 Results on Oct 28, 2024

Price target increased by 7.1% to ₹2,874

Chief Financial Officer recently sold ₹20m worth of stock

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Executive Vice President recently sold ₹5.9m worth of stock

Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Price target increased by 7.6% to ₹2,664

Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Ajanta Pharma Limited to Report Q1, 2025 Results on Jul 30, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Ajanta Pharma Limited, Annual General Meeting, Jul 18, 2024

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Price target increased by 7.4% to ₹2,440

Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

Ajanta Pharma Limited (NSEI:AJANTPHARM) announces an Equity Buyback for 1,028,881 shares, representing 0.82% for INR 2,850 million.

Full year 2024 earnings: EPS exceeds analyst expectations

Ajanta Pharma Limited to Report Q4, 2024 Final Results on May 02, 2024

Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ajanta Pharma Limited Approves Second Interim Dividend for the Year Fiscal Year 2024, Payable on or After 19th February 2024

Ajanta Pharma Limited to Report Q3, 2024 Results on Jan 31, 2024

Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Price target increased by 7.5% to ₹1,949

Second quarter 2024 earnings: EPS exceeds analyst expectations

Ajanta Pharma Limited to Report Q2, 2024 Results on Oct 31, 2023

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

Price target increased by 10.0% to ₹1,652

First quarter 2024 earnings released: EPS: ₹16.53 (vs ₹13.63 in 1Q 2023)

Ajanta Pharma Limited to Report Q1, 2024 Results on Jul 27, 2023

Insider recently sold ₹2.1m worth of stock

Ajanta Pharma Limited, Annual General Meeting, Jul 18, 2023

Insider recently sold ₹1.9m worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited to Report Q3, 2023 Results on Feb 01, 2023

Insufficient new directors

Ajanta Pharma Limited Approves Interim Dividend

Second quarter 2023 earnings: EPS misses analyst expectations

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Ajanta Pharma Limited to Report Q2, 2023 Results on Nov 03, 2022

Price target increased to ₹1,574

US FDA Announces Inspection of Pharma Limited Dahej Facility

Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Ajanta Pharma Limited to Report Q1, 2023 Results on Jul 28, 2022

Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited, Annual General Meeting, Aug 04, 2022

Investor sentiment deteriorated over the past week

Price target decreased to ₹2,335

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited to Report Q4, 2022 Results on May 10, 2022

A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Insufficient new directors

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ajanta Pharma Limited (NSEI:AJANTPHARM) announces an Equity Buyback for 1,120,000 shares, representing 1.29% for INR 2,856 million.

Insider recently sold ₹8.1m worth of stock

Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Insider recently sold ₹1.1m worth of stock

Upcoming dividend of ₹9.50 per share

Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50